American Gene Technologies
PrivateLast Round
Convertible Debt
Oct 31, 2023
Est. Valuation
$15.21M
Total Funding Raised
$73.73M
Company Overview
American Gene Technologies is a biotechnology company that develops gene and cell therapies aimed at curing infectious diseases, cancers, and inherited disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
American Gene Technologies Comparables
Compare American Gene Technologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Addimmune | 91% | |
| Excision BioTherapeutics | 82% | |
| PROVIREX Genome Editing Therapies GmbH | 77% |
American Gene Technologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Oct 31, 2023 | ||||
| Series F | Sep 22, 2023 | ||||
| M&A | Aug 9, 2023 | ||||
| Series F | Apr 22, 2022 | ||||
| VC Round | Apr 15, 2021 | ||||
Series C | Nov 1, 2015 |
Key People
Founding team and executive leadership
American Gene Technologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HealthTech Fund (An Alumni Ventures Fund) | Series D |
| ROC Venture Group | Series F |
| Ride Wave Ventures | Series F |
| NIH RADx | Grant |
| Gaingels | VC Round |
| 10X Capital Venture Acquisition Corp. III | M&A |
| Alumni Ventures | Series F, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 22, 2025
Presented at the International AIDS Society 2025 conference.
- Jul 22, 2025
Promising results from AGT103-T HIV functional cure program presented at IAS 2025.
Recent news
Latest coverage and updates
- attends_eventAug 25, 2026
American Gene will attend event Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on Sep 9th '26.
American Gene Technologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about American Gene Technologies's valuation, stock price, and market status.
Is American Gene Technologies a public or private company?
American Gene Technologies is a private company.
What is the current stock price of American Gene Technologies?
American Gene Technologies is a private company with no public stock price. No recent secondary market data is available.
How much is American Gene Technologies worth (valuation)?
American Gene Technologies's valuation is estimated at $15.2M based on funding round data.
Can I buy American Gene Technologies stock?
American Gene Technologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was American Gene Technologies's last funding round?
American Gene Technologies's most recent funding round was M&A on September 24, 2014.
Who are the main investors in American Gene Technologies?
Key investors in American Gene Technologies include 10X Capital Venture Acquisition Corp. III.
Will American Gene Technologies IPO soon?
No public IPO plans have been announced for American Gene Technologies.
How can I track American Gene Technologies secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor American Gene Technologies's secondary market activity and sign up for updates.